BioPharmSignal logoBioPharmSignal

Biotech News

PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

PTC Therapeutics, Inc. (PTCT)PTC Therapeutics, Inc.Earnings

– Robust Q2 performance with total revenue of $361 million, including $239 million of product revenue – – Full-year 2026 expected total revenue increased to $1.18 to $1.28 billion, with full-year product revenue guidance raised to $850 to $950 million – – Sephience™ (sepiapterin) Q2 2026 revenue of

Related news

PTCTPTC Therapeutics, Inc.2026-05-07 20:01 EST

PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results

PTCTPTC Therapeutics, Inc.2026-07-16 12:00 EST

PTC Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, July 30, 2026

CAPRCapricor Therapeutics2026-05-12 20:05 EST

Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

CAPRCapricor Therapeutics2026-05-04 20:05 EST

Capricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12

ABEOAbeona Therapeutics2026-08-06 11:30 EST

Abeona Therapeutics® to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026

RAREUltragenyx Pharmaceutical2026-08-04 20:05 EST

Ultragenyx Reports Second Quarter 2026 Financial Results and Corporate Update

RAREUltragenyx Pharmaceutical2026-07-28 20:05 EST

Ultragenyx to Host Conference Call for Second Quarter 2026 Financial Results and Corporate Update

MNPRMonopar2026-05-14 18:00 EST

Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

TARAProtara Therapeutics2026-05-13 12:00 EST

Protara Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update

ABEOAbeona Therapeutics2026-05-04 12:30 EST

Abeona Therapeutics® Announces Date of First Quarter Financial Results

View all latest news

PTC Therapeutics, Inc.

Rare-Disease Medicines PTC Therapeutics discovers, develops and commercializes medicines for children and adults with rare disorders. Its portfolio spans metabolic, neurologic and neuromuscular diseases. Commercial Portfolio Sephience, or sepiapterin, is a therapy for phenylketonuria and represents a growing global commercial franchise....

Recent company news

PTCTPTC Therapeutics, Inc.2026-07-30 20:01 EST

PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

PTCTPTC Therapeutics, Inc.2026-07-16 12:00 EST

PTC Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, July 30, 2026

PTCTPTC Therapeutics, Inc.2026-06-17 20:30 EST

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PTCTPTC Therapeutics, Inc.2026-06-16 03:14 EST

PTC Therapeutics Announces Pricing of Convertible Notes Offering to Refinance 2026 Convertible Notes

PTCTPTC Therapeutics, Inc.2026-06-15 11:00 EST

PTC Therapeutics Announces Proposed Convertible Notes Offering to Refinance 2026 Convertible Notes

Stock data

Close
70.85 USD
Market cap
5.66B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States